After many years being an active member of the International Society for Experimental Hematology (ISEH), Dr. Menéndez finally ran for a position on its governing body, the Board of Directors. In his candidate statement, he praised the society for fostering the integration and collaboration among researchers worldwide and being a reference, even a home, for all experimental haematologists regardless of their career stage. Dr. Menéndez will put his experience at the service of the Society to help promote scientific excellence, bridge the gap between fundamental research and technology transfer, facilitate networking and mentorship and ensure transparency and continuous improvement. At the Josep Carreras Leukaemia Research Institute, Dr. Menéndez leads the Stem cell biology, developmental leukaemia and immunotherapy lab, based at the Barcelona’s Hospital Clínic location. His main field of expertise is the development of next-generation CAR-T cell therapies for B, T and myeloid childhood leukaemia. The turnover of the Board of Directors came after the 53rd annual meeting, held in Chicago (USA) and will be in duty for the 2024-2027 period.